| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Wang Xie,Yi-Zhen | Chairman | 27.82% | CHINA CHEMICAL & PHARMACEUTICAL CO., LTD. |
| Wang,Hou-Kai | Vice Chairman | 27.82% | CHINA CHEMICAL & PHARMACEUTICAL CO., LTD. |
| Wang,Hou-Jie | Director | 2.18% | WANG MINNING MEMORIAL FOUNDATION |
| Wu,Shi-Xuan | Director | 2.18% | WANG MINNING MEMORIAL FOUNDATION |
| Guan,Xin | Independent Director | 0.00% | |
| Wang,Guo-Qiang | Independent Director | 0.00% | |
| Li,Ming-Jie | Independent Director | 0.00% |
Change Company Name to SINOCHEM SYNTHETIC BIOTECHNOLOGY CO., LTD. (FORMER NAME: CHINA CHEMICAL SYNTHETIC INDUSTRY CO., LTD.)
2022/06/14
Change Company Name to CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD.
2022/06/14
Change Capital to 1,600,000,000
2021/07/16
Change Person in Charge to Wang Xie,Yi-Zhen
2020/11/30
下載完整報告查看完整數據
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 192,952 | 1,347,375 | 2,086,441 |
| Operating cost | 132,421 | 953,057 | 1,329,133 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 60,531 | 394,318 | 757,308 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 60,531 | 394,318 | 757,308 |
| Operating expenses | 75,109 | 387,976 | 476,499 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -14,578 | 6,342 | 280,809 |
| Non-operating income and expenses | 19,008 | 50,880 | 52,678 |
| Net profit (loss) before tax | 4,430 | 57,222 | 333,487 |
| Income tax expense (benefits) | -2,888 | 4,190 | 68,578 |
| Net profit (loss) of ongoing business for the current period | 7,318 | 53,032 | 264,909 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 7,318 | 53,032 | 264,909 |
| Other comprehensive profit (loss), net | 11,376 | 15,721 | -6,865 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 18,694 | 68,753 | 258,044 |
| Net profit (loss) attributable to owners of parent company | 7,318 | 53,032 | 264,909 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | 0 |
| Comprehensive profit (loss) attributable to owners of parent company | 18,694 | 68,753 | 258,044 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | 0 |
| Basic earnings per share (yuan) | 0 | 0 | 3 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 76,143 | 467,654 | -66,274 |
| Net cash inflows (outflows) from investing activities | -22,532 | -100,099 | -461,324 |
| Net cash inflow (outflow) from financing activities | -939 | -415,721 | 496,574 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 179 | 872 | -21 |
| Increase (decrease) in cash and cash equivalents in the current period | 52,851 | -47,294 | -31,045 |
| Beginning balance of cash and cash equivalents | 222,275 | 269,569 | 300,614 |
| Ending balance of cash and cash equivalents | 275,126 | 222,275 | 269,569 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 1,418,113 | 1,441,225 | 1,787,783 |
| Non-current asset | 3,327,000 | 3,321,513 | 3,383,868 |
| Total asset | 4,745,113 | 4,762,738 | 5,171,651 |
| Current liability | 492,603 | 425,288 | 831,412 |
| Non-current liability | 876,876 | 980,510 | 990,004 |
| Total liability | 1,369,479 | 1,405,798 | 1,821,416 |
| share capital | 775,600 | 775,600 | 775,600 |
| Equity - secruity token | - | - | - |
| capital reserve | 334,526 | 334,526 | 334,526 |
| retained earning | 2,319,289 | 2,311,979 | 2,295,585 |
| Other equity | -53,781 | -65,165 | -55,476 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 3,375,634 | 3,356,940 | 3,350,235 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | 0 | 0 |
| Total Equity | 3,375,634 | 3,356,940 | 3,350,235 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 43 | 43 | 43 |
